Latest BDX News

BCAL Diagnostics has reported strong early commercial uptake of its BREASTEST plus non-invasive breast cancer diagnostic test, alongside a new partnership with Cancer Care Associates to expand market reach.

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.